Reducing unnecessary thyroid hormone use in older adults
Optimizing Care for Older Adults Through Thyroid Hormone Deprescribing
This study is testing a new program to help doctors give less unnecessary thyroid hormone to older adults by providing them with better information and support.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 900 (estimated) |
| Ages | 65 Years and up |
| Sex | All |
| Sponsor | University of Michigan Academic / other |
| Locations | 3 sites (San Francisco, California and 2 other locations) |
| Trial ID | NCT06629272 on ClinicalTrials.gov |
What this trial studies
This study tests a new intervention called D-THIO, aimed at helping healthcare providers reduce overtreatment of thyroid hormone in older adults. It involves a multi-level approach that includes educational materials for patients and guidance for providers. The trial will take place at three sites and will assess the effectiveness of D-THIO compared to standard care in improving provider and patient knowledge, as well as reducing inappropriate thyroid hormone use. The study will also explore factors that affect the implementation of this deprescribing strategy in various healthcare settings.
Who should consider this trial
Good fit: Ideal candidates are adults aged 65 and older who are currently on thyroid hormone therapy and have low serum TSH levels or are using thyroid hormone for inappropriate reasons.
Not a fit: Patients with thyroid cancer, secondary hypothyroidism, or those who have had a total thyroidectomy may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the risks associated with thyroid hormone overtreatment in older adults.
How similar studies have performed: Other studies have shown promise in deprescribing interventions, making this approach both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Patient Eligibility: Inclusion Criteria: 1. age 65 years and older 2. on thyroid hormone therapy and have a serum Thyroid-stimulating hormone (TSH) \<0.5 mIU/L or are on thyroid hormone therapy for an inappropriate indication 3. English speaking 4. without cognitive impairment Exclusion Criteria: 1\) Patients with a diagnosis of thyroid cancer, secondary hypothyroidism, history of total thyroidectomy or hospitalization in the past 3 months will be excluded. Provider eligibility: Inclusion: Primary care physicians, endocrinologists, geriatricians, and Advanced Practice Providers (APPs) who practice at University of Michigan, Henry Ford Health System or University of California San Fransico (UCSF) and who prescribe thyroid hormone for eligible patients identified above will be eligible for study participation. Exclusion: Providers who don't prescribe thyroid hormone.
Where this trial is running
San Francisco, California and 2 other locations
- University of California San Francisco — San Francisco, California, United States (Recruiting)
- University of Michigan — Ann Arbor, Michigan, United States (Recruiting)
- Henry Ford Health System — Detroit, Michigan, United States (Recruiting)
Study contacts
- Principal investigator: Maria Papaleontiou — University of Michigan
- Study coordinator: Brittany Gay
- Email: bbartol@umich.edu
- Phone: 734-763-8608
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.